Hangzhou Minsheng Pharmaceutical Co., Ltd.
-
Founded in:
1963-11-29 -
Country:
China -
Address:
No. 36, Linping Avenue, Donghu Street, Linping District, Hangzhou City, Zhejiang Province -
Tax NO.:
913301101430685558 -
Registered Funds:
88.97 million yuan -
Website:
-
Email:
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Atropine |
Not described in detail
More
Not described in detail |
51-55-8 | 6 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Spironolactone |
This drug has a similar structure to aldosterone and is a competitive inhibitor of aldosterone. It acts on the distal convoluted tubule and collecting duct, blocking the Na+-K+ and Na+-H+ exchanges, resulting in increased excretion of Na+, C1- and water, reduced excretion of K+, Mg2+ and H+, and uncertain effects on Ca2+ and P3-. Since this drug only acts on the distal convoluted tubule and collecting duct, and has no effect on other segments of the renal tubule, its diuretic effect is weak. In addition, this drug also has effects on aldosterone target organs other than the renal tubule.
More
This drug has a similar structure to aldosterone and is a competitive inhibitor of aldosterone. It acts on the distal convoluted tubule and collecting duct, blocking the Na+-K+ and Na+-H+ exchanges, resulting in increased excretion of Na+, C1- and water, reduced excretion of K+, Mg2+ and H+, and uncertain effects on Ca2+ and P3-. Since this drug only acts on the distal convoluted tubule and collecting duct, and has no effect on other segments of the renal tubule, its diuretic effect is weak. In addition, this drug also has effects on aldosterone target organs other than the renal tubule. |
52-01-7 | 18 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Magnesium sulfate |
Magnesium ions can inhibit the activity of the central nervous system, inhibit the release of acetylcholine at the motor nerve-muscle junction, block conduction at the neuromuscular junction, reduce or relieve muscle contraction, and at the same time have a dilating effect on vascular smooth muscle, dilate spasmodic peripheral blood vessels, and lower blood pressure. Therefore, it has a preventive and therapeutic effect on eclampsia. It also has an inhibitory effect on uterine smooth muscle contraction and can be used to treat premature delivery.
More
Magnesium ions can inhibit the activity of the central nervous system, inhibit the release of acetylcholine at the motor nerve-muscle junction, block conduction at the neuromuscular junction, reduce or relieve muscle contraction, and at the same time have a dilating effect on vascular smooth muscle, dilate spasmodic peripheral blood vessels, and lower blood pressure. Therefore, it has a preventive and therapeutic effect on eclampsia. It also has an inhibitory effect on uterine smooth muscle contraction and can be used to treat premature delivery. |
7487-88-9 | 33 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| Fenofibrate |
This product is a blood lipid regulating drug of clofibric acid derivatives. It reduces blood low-density lipoprotein, cholesterol and triglycerides by inhibiting the production of very low-density lipoprotein and triglycerides and increasing their catabolism at the same time; it also increases the production of apolipoprotein A1 and A11, thereby increasing high-density lipoprotein. This product also has the effect of reducing blood uric acid in normal people and patients with hyperuricemia. Animal experiments have shown that fenofibrate is teratogenic and carcinogenic.
More
This product is a blood lipid regulating drug of clofibric acid derivatives. It reduces blood low-density lipoprotein, cholesterol and triglycerides by inhibiting the production of very low-density lipoprotein and triglycerides and increasing their catabolism at the same time; it also increases the production of apolipoprotein A1 and A11, thereby increasing high-density lipoprotein. This product also has the effect of reducing blood uric acid in normal people and patients with hyperuricemia. Animal experiments have shown that fenofibrate is teratogenic and carcinogenic. |
49562-28-9 | 63 |
| Name | Description | Content | CAS NO. | Registered Holders |
|---|---|---|---|---|
| L-ASPARTIC ACID |
As the precursor of oxaloacetate in the body, it plays an important role in the tricarboxylic acid cycle and participates in the ornithine cycle, combining ammonia and carbon dioxide to form urea. It has a strong affinity for cells and can be used as a carrier of potassium and magnesium ions to help them enter cells, increase the concentration of potassium and magnesium in cells, accelerate the tricarboxylic acid cycle of liver cells, and have a certain effect on improving liver function and reducing serum bilirubin concentration. It is metabolized and excreted from the body through the kidneys.
More
As the precursor of oxaloacetate in the body, it plays an important role in the tricarboxylic acid cycle and participates in the ornithine cycle, combining ammonia and carbon dioxide to form urea. It has a strong affinity for cells and can be used as a carrier of potassium and magnesium ions to help them enter cells, increase the concentration of potassium and magnesium in cells, accelerate the tricarboxylic acid cycle of liver cells, and have a certain effect on improving liver function and reducing serum bilirubin concentration. It is metabolized and excreted from the body through the kidneys. |
79-91mg | 6899-03-2 | 18 |
| Potassium |
As an ion carrier, it enters cells, increases the concentration of potassium in cells, accelerates the tricarboxylic acid cycle of liver cells, and has a certain effect on improving liver function. It is metabolized and excreted from the body through the kidneys.
More
As an ion carrier, it enters cells, increases the concentration of potassium in cells, accelerates the tricarboxylic acid cycle of liver cells, and has a certain effect on improving liver function. It is metabolized and excreted from the body through the kidneys. |
10.6-12.2mg | 0 | |
| Magnesium |
As an ion carrier, it enters cells, increases the concentration of magnesium in cells, accelerates the tricarboxylic acid cycle of liver cells, and has a certain effect on improving liver function. It is metabolized and excreted from the body through the kidneys.
More
As an ion carrier, it enters cells, increases the concentration of magnesium in cells, accelerates the tricarboxylic acid cycle of liver cells, and has a certain effect on improving liver function. It is metabolized and excreted from the body through the kidneys. |
3.9-4.5mg | 0 |